Tag: drug-coated balloon

pooled

Pooled analysis of four RCTs finds drug-coated balloons superior to plain...

A pooled analysis of four randomised controlled trials finds drug-coated balloon (DCB) angioplasty superior to plain angioplasty in patients with femoropopliteal artery disease, irrespective...

Meta-analysis finds a higher risk of death in the long term...

 Konstantinos Katsanos (Patras, Greece) tells Interventional News about new data from a meta-analysis that has been published in the Journal of the American Heart...

First US patient enrolled in ILLUMENATE BTK study of Stellarex 0.014...

The first US patient has been enrolled in the Stellarex ILLUMENATE below-the-knee (BTK) investigational device exemption (IDE) study, led by principal investigators Bill Gray...
stellarex

Similar patency outcomes in women and men treated with Stellarex DCB

A study presented at VIVA 2018 (5–8 November, Las Vegas, USA) by Maureen Kohi, associate professor of Clinical Radiology, University of California, San Francisco,...

Consider intravascular lithotripsy when treating calcified femoropopliteal arteries

 Treating severely calcified arteries by endovascular means is still a challenge, although atherectomy, stents and lithotripsy are all techniques that are employed.  Lithotripsy (also...
Lutonix

Interim results of the Lutonix drug-coated balloon in a complex patient...

This article is sponsored by BD. In a complex patient population with advanced, symptomatic below-the-knee peripheral artery disease, treatment with the Lutonix drug-coated balloon (BD)...

Terumo gets CE mark for Kanshas drug-coated balloon catheter for lower...

Terumo has announced receiving the CE mark for its Kanshas drug-coated balloon catheter used in the treatment of lower extremity peripheral arterial disease. With...

New CMS reimbursement code “severely underpays” for drug-coated balloons

Drug-coated balloon (DCB) angioplasty devices have been categorised by the US Centers for Medicare and Medicaid Services (CMS) into the same billing code as...

“Fantastic” live case demonstrates potential value of intravascular lithotripsy

In an exciting session at the Charing Cross Symposium (CX; 24-27 April, London, UK), the audience witnessed the demonstration of a novel treatment strategy...

CX 2018: Ulf Teichgräber discusses EffPAC trial 12-month results

Ulf Teichgräber, Jena, Germany, discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its robust body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical...

US FDA grants Medtronic investigational device exemption for new In.Pact Admiral...

Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the In.Pact Admiral...

Results from Asia and Belgium demonstrate consistent results from Medtronic In.Pact...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s In.Pact Admiral drug-coated balloon across...

Encouraging results for Biotronik’s Passeo-18 Lux drug-coated balloon and Pulsar-18 bare...

Interim data presented at the 2017 Leipzig Interventional Course (LINC; 24-27 January, Leipzig, Germany) has demonstrated encouraging results for Biotronik’s dedicated lower limb intervention...

Spectranetics gets CE mark for Stellarex 0.014” drug-coated balloon

Spectranetics has announced that its Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark. The device is designed to treat small vessels, below-the...

UK NICE publishes Medtech Innovation Briefing on Lutonix

The UK National Institute for Health and Care Excellence (NICE) has developed a Medtech Innovation Briefing (MIB) on the Lutonix drug-coated balloon (DCB) for...